# Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

> **NCT00035594** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 928 (—)

## Conditions studied

- Neutropenia

## Interventions

- **DRUG:** pegfilgrastim

## Key facts

- **NCT ID:** NCT00035594
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** 2004-02
- **Final completion:** 2004-06
- **Target enrollment:** 928 (—)
- **Last updated:** 2013-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035594, "Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00035594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*